Drug Profile
Filgrastim biosimilar - Fuji Pharmaceutical/Mochida Pharmaceutical/Kidswell Bio
Alternative Names: Filgrastim BS; FSK-0808; GBS 001Latest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Fuji Pharmaceutical; Gene Techno Science; Mochida Pharmaceutical
- Developer Fuji Pharmaceutical; Kidswell Bio; Mochida Pharmaceutical
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 01 Jul 2021 Gene Techno Science is now called Kidswell Bio
- 15 Nov 2011 Biosimilar filgrastim is still in phase II/III trials for Neutropenia in Japan
- 30 Jul 2010 Phase-II/III clinical trials in Neutropenia in Japan (Parenteral)